Eriksson, who was elected at an extraordinary general meeting on 28 October, resigned on 16 November at his own request. Øvlesen followed on 17 November. He said the demands and responsibilities of the chair role have increased and that he is no longer best placed to fulfill the requirements of the position. The board now has four members, the minimum required by the company’s articles of association, and will announce a designated chair as soon as possible.

The changes come as Cereno prepares a rights issue of around SEK 400 million to fund its clinical development, including the Phase IIb EPIMODE trial of its lead candidate CS1 in pulmonary arterial hypertension.

“We respect Jeppe’s decision and thank him for his contributions and commitment during his time on the Board,” says Sten R. Sörensen, CEO of Cereno Scientific.